Google
XCUR — EXICURE INC (Healthcare >> Biotechnology)
XCUR FAQ
What is XCUR's ROE?
EXICURE INC reports a Return on Equity (ROE) of -466.35%.
What is XCUR's dividend yield?
EXICURE INC offers a dividend yield of 0.00%.
What is XCUR's Deepscope Quality Score?
Deepscope rates XCUR's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy XCUR?
Deepscope's AI Timing Score for XCUR is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does XCUR belong to?
EXICURE INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 2.96
Price
-0.20
(-6.33%)
Day Change
|
|
|---|
XCUR, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROE is decreasing significantly
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 91 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 2.96 |
| PBV / Sector |
9.45 / 4.58
|
| Earning Per Share | -1.46 |
| PE / Sector |
N/A / 17.10
|
| PEG or PE/Growth / Sector |
N/A / 0.52
|
| Average 1M Daily Value |
0.04 M
GREAT
|
| Average 1W Daily Value |
0.05 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
47% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-05 09:12:01 |
| Symbol | XCUR |
| Name | EXICURE INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 6.37 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 19.82 / 8,655.90 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 400 Seaport Court, Redwood City, CA, United States, 94063
Phone: 847 673 1700
Website: https://www.exicuretx.com
Sector: Healthcare >> Biotechnology
Description: Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
